Digest Network Come funziona
Network
/
Società
JC
Non verificato

JCR Pharmaceuticals Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

44 comunicati stampa

Guarda tutti i comunicati
14/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
02/10/2026
Multimedialità
Mercato del lavoro
Industria
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
28/09/2026
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
11/09/2026
Multimedialità
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
21/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
17/06/2026
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
08/06/2026
Fiere
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
JCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
28/05/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Eventi
Fiere
Industria
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
18/05/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0
11/05/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
Fonte
JCR Pharmaceuticals Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0